DANIEL BRADBURY
CIK 1236397 · CHAIRMAN · last filed 2026-06-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$22.53M
Companies
11
Total Filings
264
Lifetime Open-Market Net
-$176.51M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CSTL | Director | 35,631 | $20.70 | $737.6K | -$160.98M | 91 | 2026-06-01 |
| EQ | CHAIRMAN | 2,969,596 | $2.81 | $8.34M | $0 | 11 | 2026-05-29 |
| VANI | Director | — | $1.10 | — | $0 | 6 | 2026-01-05 |
| INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Director | 39,471 | $19.00 | $749.9K | $500.0K | 9 | 2023-05-25 |
| Nuvation Bio Inc. (NUVB.WS) Delisted | Director | 25,000 | $0.01 | $128 | $0 | 1 | 2021-02-26 |
| GERN | Director | 51,323 | $1.15 | $59.0K | $0 | 12 | 2019-04-01 |
| CORT | Director | 130,575 | $82.91 | $10.83M | -$480.2K | 16 | 2019-02-12 |
| ILMN | Director | 15,924 | $160.97 | $2.56M | -$14.97M | 79 | 2017-05-26 |
| BioMed Realty Trust Inc (BMRpA) Delisted | Director | 4,139 | — | — | $0 | 1 | 2013-01-03 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | President & Chief Executive Of | 127,235 | — | — | -$574.8K | 30 | 2012-07-26 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 35,714 | — | — | $0 | 3 | 2008-02-15 |
Recent Filings · Page 12 of 27
264 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-12-12 | EQ | Grant (A) | — | $0 | EDGAR |
| 2019-07-31 | CSTL | Conv (C) | +908,578 | $908.8K | EDGAR |
| 2019-06-21 | INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted | Grant (A) | +1,570 | $0 | EDGAR |
| 2019-04-01 | GERN | Grant (A) | +9,036 | $0 | EDGAR |
| 2019-02-15 | EQ | Grant (A) | — | $0 | EDGAR |
| 2019-02-12 | CORT | Gift (G) | −25,000 | $0 | EDGAR |
| 2019-01-02 | GERN | Grant (A) | +15,000 | $0 | EDGAR |
| 2018-10-16 | EQ | Other (J) | +48,495 | $543.1K | EDGAR |
| 2018-09-28 | GERN | Grant (A) | +8,523 | $0 | EDGAR |
| 2018-08-22 | CORT | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.